Delighted to be named a 2025 finalist in the HLTH Europe Startup Pitch, sponsored by Haleon! Honoured to share the stage with some of the most innovative healthtech startups in Europe. See you in Amsterdam. 🇳🇱

We believe that true success in business must be measured not just by commercial milestones, but by the positive impact we create. To us, being a B Corp is more than a certification – it’s a daily commitment to balancing people, planet, profit, and purpose. B Lab’s rigorous standards provide a clear framework for accountability …

🎧 We loved this recent BBC Radio interview with Professor Siobhan Quenby MBE, who is leading the clinical trial of our progesterone-loaded Callavid at University Hospitals Coventry and Warwickshire (UHCW) NHS Trust. 🔗 Listen to the clip: https://lnkd.in/e9GkFDaD Professor Quenby shares how our pioneering drug delivery technology could support women globally experiencing threatened miscarriage — …

Grateful to BBC News for spotlighting our work on progesterone-Callavid®, our novel drug delivery technology aimed at helping treat threatened miscarriage. “The current delivery method can leak and cost the [British economy and] NHS up to £236m per year, health economists say. University Hospitals Coventry and Warwickshire (UHCW) NHS Trust is leading the trial and …

Trust leads clinical trial of pioneering product to tackle threatened miscarriage 8 April 2025 Experts from University Hospitals Coventry and Warwickshire (UHCW) NHS Trust are to lead a clinical trial of a novel device aimed at addressing threatened miscarriage. More than 150,000 women a year in the UK could be helped by Callavid® which is designed …

[From NIHR: National Institute for Health and Care Research] We have awarded £1 million in funding to a first of its kind technology that’s being trialled to address threatened miscarriage. Currently, over 150,000 women in the UK experience threatened miscarriage a year. If approved, the device would become the world’s first drug-device combination to treat …

Pioneering technology to address threatened miscarriage secures £1 million funding and moves towards clinical trials • Scientists developing a pioneering device designed to address threatened miscarriage have secured £1 million in NIHR funding to begin clinical trials • Designed to deliver vital doses of progesterone, the Callavid® device stands to help over 150,000 women each …

We’ve achieved some exciting IP milestones for Calla Lily Clinical Care; making strong progress in building a robust IP strategy and IP portfolio to protect and advance our innovations in women’s health. 💥 China Patent Grant for our Drug Delivery Device 🌏 At long last, one of our vaginal drug delivery applications in China has …

Our co-founders Lara and Thang have been named in the annual ‘200 Trailblazing Leaders in Women’s Health and FemTech’ for the second year running.  It’s a real who’s who of the influential leaders working to improve the access and quality of healthcare for women worldwide.  We’re delighted at the recognition for Lara & Thang and …

🔊 Our co-founder, Dr Lara Zibners shares candid insights in a compelling podcast interview with Femmehealth Ventures. If you’ve ever thought, “There has to be a better way,” when it comes to drug delivery for women’s health, this episode is a must-listen. Lara shares her personal journey through IVF, the challenges of existing solutions, and …